Michel Pieren, Ana Abáigar Gutiérrez-Solana, Rosa María Antonijoan Arbós, Gary W Boyle, Myriam Davila, Maria Davy, Marc Gitzinger, Lisa Husband, María S Martínez-Martínez, Dolores Ochoa Mazarro, Eleni Pefani, Sophie L Penman, Modesto J Remuiñán, Georgios Vlasakakis, Markus Zeitlinger, Glenn E Dale
BACKGROUND: The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo. OBJECTIVES: A Phase 1, double-blind, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK) and food effect of alpibectir administered as single and multiple oral doses in healthy volunteers (NCT04654143). METHODS: Eighty participants were randomized...
April 24, 2024: Journal of Antimicrobial Chemotherapy